Related Experiment Videos
Long-term methotrexate therapy for rheumatoid arthritis
C J Scully1, C J Anderson, G W Cannon
1Division of Rheumatology, University of Utah, Salt Lake City.
Seminars in Arthritis and Rheumatism
|April 1, 1991
Summary
Methotrexate (MTX) is often discontinued in rheumatoid arthritis (RA) patients due to adverse reactions, not loss of efficacy. Long-term MTX use is limited by side effects, impacting treatment adherence and patient outcomes.
Area of Science:
- Rheumatology
- Clinical Pharmacology
Background:
- Methotrexate (MTX) is a cornerstone therapy for rheumatoid arthritis (RA).
- Long-term efficacy and safety data for MTX in RA patients are crucial for clinical decision-making.
Purpose of the Study:
- To evaluate the long-term clinical course of rheumatoid arthritis (RA) patients treated with methotrexate (MTX).
- To identify reasons for MTX discontinuation and the prevalence of adverse drug reactions (ADRs).
Main Methods:
- Retrospective review of 124 rheumatoid arthritis (RA) patients treated with methotrexate (MTX).
- Analysis of treatment duration, reasons for discontinuation, and reported adverse drug reactions over a 5-year period.
Main Results:
- 31% of RA patients continued MTX with clinical benefit after 5 years.
- ADRs led to permanent MTX discontinuation in 44 patients; nausea and stomatitis were common.
- 93% of patients reported at least one ADR, but most did not require permanent discontinuation.
- Long-term MTX therapy was primarily limited by adverse reactions rather than loss of efficacy.
Conclusions:
- Adverse reactions are a significant factor limiting long-term methotrexate (MTX) therapy in rheumatoid arthritis (RA) patients.
- While ADRs are common, they do not always necessitate treatment cessation, highlighting the need for careful management.